Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
There is no clear treatment for patients with limited cutaneous Kaposi sarcoma (KS).
Radiation and injection of vinblastine both have side effects that may not be acceptable.
Nivolumab has been used to treat more extensive KS when given intravenously. This is, to the
investigators' knowledge, the first trial to see if nivolumab can be used as treatment in the
form of an injection into KS lesion.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)